Menu

1 / 5

The Next Chapter of mRNA

#time#mrna#bancel#moderna#cancer
Long article (4810 words) — no AI summary yet.
Reading 0:00
15s threshold

Inside the new manufacturing site for intismeran, a personalized mRNA-based cancer vaccine at Moderna in Marlborough, Massachusetts on Oct. 19, 2026. Tony Luong for TIME

It’s been a very good year for Stéphane Bancel. On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public. He’s recounting the biotech’s rocky road turning an unproven, scientifically dismissed approach—using messenger RNA, or mRNA, the genetic code that instructs cells to make proteins—into a platform for producing new categories of medicines.

Fifteen years ago, Bancel had his doubts. At the time, there were no approved mRNA-based products on the market, and most scientists would have agreed that mRNA was too unstable to form the basis of a new class of medical treatments.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.